We examined in the present study whether human gastric cancer cells express peroxisome proliferator-activated receptor γ γ γ γ (PPARγ γ γ γ), the effect of PPARγ γ γ γ activation by troglitazone, a selective ligand, on cellular growth, and the mechanism of the growth arrest by troglitazone in gastric cancer cells. Kip1 in all four gastric cancer cell lines. Since it has been reported that the ubiquitin-proteasome system plays a vital role in the degradation of p27
Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily, which includes receptors for steroids, thyroid hormone, vitamin D and retinoic acid. 1) PPARγ is expressed at high levels in adipose tissue and functions as a key molecule in adipocyte differentiation. 2, 3) In addition to adipose tissue, PPARγ expression is detected in a wide variety of tumor cells. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In the tumor cells, PPARγ activation by highaffinity ligands could inhibit cell growth. Thus, PPARγ is involved in not only lipid metabolism, but also cellular proliferation in cancer cells. It has therefore been suggested that PPARγ is a possible molecular target for cancer treatment. We have reported that MKN-45 cells, a poorly differentiated gastric cancer cell line, express PPARγ, and PPARγ ligands such as troglitazone and pioglitazone induce growth inhibition. 13) Little is known, however, about whether other human gastric cancer cells express PPARγ, and whether PPARγ ligands induce growth arrest in them.
Although increasing evidence has established that PPARγ activation induces growth arrest in cancer cells, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] the molecular mechanism of the growth inhibition by PPARγ ligands is not understood. With regard to this point, we have very recently demonstrated that p27 Kip1 , a cyclin-dependent kinase inhibitor (CDKI), 16, 17) may be a key molecule in the cell growth inhibition by troglitazone in human pancreatic cancer cells. 14) Little is known, however, about whether p27
Kip1 is up-regulated by PPARγ ligands in cancer cells other than pancreatic cancer cells. In addition, there is no report on the mechanism of p27 Kip1 protein accumulation by PPARγ ligands.
In the present study, we tried to clarify whether PPARγ is expressed in human gastric cancer cell lines, MKN-28, MKN-45, MKN-74 and KATO-III cells, whether troglitazone can induce growth inhibition in the four gastric cancer cells, whether p27
Kip1 is also increased by troglitazone in gastric cancer cells, and the mechanism of the increase in p27
Kip1 by troglitazone. 1 To whom correspondence and reprint requests should be addressed. E-mail: okumurat@asahikawa-med.ac.jp gastric cancer, respectively. Gastric cancer cells were cultured in RPMI-1640 medium (GIBCO, Grand Island, NY) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin, and 10% fetal bovine serum. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. Chemicals and treatments Troglitazone 18) was kindly provided by Sankyo Pharmaceutical Co. (Tokyo) and was dissolved in dimethyl sulfoxide (DMSO). The final concentration of DMSO was 0.1% in the culture medium. RNA extraction Total RNA was extracted from cultured cells using a modified version of the acid guanidinium thiocyanate/phenol/chloroform method employing a single reagent (RNA-STAT 60, TelTest, Inc., Friendswood, TX). 19) Samples were dissolved with diethyl pyrocarbonate-treated water (RNase-free). To remove contaminating genomic DNA, the RNA was treated with 10 µl of RQ1, RNase-DNase (Promega, Madison, WI), 0.5 µl of RNase inhibitor (TaKaRa Shuzou Co., Otsu) and 10 µl of 10× DNase buffer (400 mM Tris-HCl at pH 7.9, 100 mM NaCl, 60 mM MgCl 2 and 100 mM CaCl 2 ) in a final volume of 100 µl for 30 min at 37°C. RNA samples were purified by phenol-chloroform extraction and isopropanol precipitation. The resultant RNA samples were quantified using a spectrophotometer at a wavelength of 260 nm. The integrity of the isolated RNA samples was analyzed electrophoretically on agarose gel, followed by staining with ethidium bromide. Reverse transcription PCR (RT-PCR) An aliquot of 1 µg of total RNA from each sample was reverse-transcribed to cDNA using a First-Strand cDNA Synthesis Kit (Pharmacia LKB Biotechnology, Uppsala, Sweden) according to the manufacturer's instructions, with oligo(dT) primer. For detection of the human PPARγ mRNA, a combination of a sense primer of 5′-TCTCTCCGTAATGGA-AGACC-3′ and an antisense primer of 5′-GCATTATGA-GACATCCCCAC-3′ was used as described previously. 20) The amplification was carried out in a 100 µl mixture containing 1 µl of the above cDNA product (corresponding to cDNA synthesized from 67 ng of total RNA), 0.4 µM each of the sense and antisense primers, 10 mM Tris HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 µM dNTPs, and 2.5 units of Taq DNA polymerase (TaKaRa Shuzou Co.). The reaction conditions were as follows; initial denaturation at 95°C for 2 min and 40 cycles of amplification (95°C for 40 s, 55°C for 50 s and 72°C for 50 s), followed by a final extension step of 7 min at 72°C. The PCR reaction products were separated electrophoretically in a 2% agarose gel and stained with ethidium bromide. Northern analysis Ten micrograms of total RNA denatured in formamide and formaldehyde was electrophoresed through 1% formaldehyde-containing agarose gels. After electrophoresis, the RNA was transferred to a nylon membrane (Hybond N, Amersham International, Buckinghamshire, UK) by capillary blotting and then fixed with a UV cross linker (FUNA-UV-LINKER, Funakoshi, Tokyo). Prehybridization was performed at 42°C for 2 h in 50% formamide, 25 mM sodium phosphate (pH 6.5), 0.1% sodium dodecyl sulfate (SDS), 5× SSC, 5× Denhardt's solution and 100 µg/ml denatured salmon sperm DNA. Hybridization was carried out at the same temperature for 20 h in the same solution with 32 P-labeled cDNA probes. The probe for PPARγ was amplified by PCR using MKN-45 cell cDNA as the template and sequenced. β-Actin cDNA probe (Wako Chemicals Industries, Osaka) was used as an internal control. The membrane was washed under appropriately stringent conditions, and the hybridization signals were analyzed with a bioimaging analyzer system (Fuji-BAS, Fuji Photo Film Co., Tokyo) or by autoradiography using XAR film (Eastman Kodak, Rochester, NY). Western blot analysis Total protein was extracted from each human gastric cancer cell line. Protein concentrations were measured using Bio-Rad Protein Assay Reagent (Bio-Rad Lab., Richmond, CA) following the manufacturer's suggested procedure. Fifty micrograms of protein was separated on a 10% Tris-Glycine gel. After electrophoresis, the proteins were transferred to nitrocellulose membrane (Amersham Life Science, Inc., Piscataway, NJ), blocked overnight in PBS-Tween (PBS-T) with 10% skim milk at 4°C, then reacted with primarily monoclonal antibody against human PPARγ (Santa Cruz Biotechnology, Santa Cruz, CA) and washed. After reaction with horseradish peroxidase-conjugated anti-mouse IgG, immune complexes were visualized by using the ECL detection reagents (Amersham, Buckinghamshire, UK) following the manufacturer's suggested procedure. Simultaneously, mouse immunoglobulin G1 κ monoclonal immunoglobulin (Pharmingen, San Diego, CA) was used as an isotype control. Cell growth assay To evaluate the effect of PPARγ activation on cell growth, cells were seeded on a 96-well cell culture cluster (Corning, Inc., Corning, NY) at a concentration of 1×10 4 /well in a volume of 100 µl. Twenty-four hours later, each well was incubated with troglitazone at several concentrations. Cell numbers were measured colorimetrically using a Cell Counting Kit (Dojindo, Kumamoto) with an ImmunoMini NJ-2300 (NJ InterMed, Tokyo) at a test wavelength of 450 nm. This assay is based on the cleavage of the 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1) by mitochondrial dehydrogenase in viable cells. 21) In comparison with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, WST-1 is more sensitive and does not require cells to be solubilized. Cell cycle assay by flow cytometry Gastric cancer cells treated with troglitazone or DMSO for 0 or 48 h were collected by centrifugation, and permeabilized with ice-cold 70% ethanol for at least 1 h. They were washed with PBS, and treated with PBS containing 100 mg/ml RNase A (DNase free) at 37°C for 30 min. Following centrifugation, the cells were resuspended in PBS containing 50 mg/ ml propidium iodide and stained at 37°C for 30 min. DNA contents were analyzed by FACScan (Becton Dickinson).
MATERIALS AND METHODS

Cell culture
Protein expression of cyclin-dependent kinase inhibitors, p21
Cip1/Waf1 and p27 Kip1 detected by western blot analysis The effect of troglitazone on the expression of CDKIs, p27
Kip1 and p21 Cip1/Waf1 in gastric cancer cells was studied by western blot analysis. The cells were treated with several doses of troglitazone and total proteins were extracted from the cells at several time points. Protein concentrations were measured using Bio-Rad Protein Assay Reagent (Bio-Rad Lab.) following the manufacturer's suggested procedure. Fifty micrograms of protein was separated by 5-20% SDS-PAGE (Ready Gels J, BioRad Lab.). After electrophoresis, the proteins were transferred to nitrocellulose membrane (Amersham Life Science, Inc.), blocked in TBS with 10% skim milk at room temperature for 60 min, then reacted overnight with goat polyclonal antibody against p27
Kip1 or goat anti-p21
Cip1/Waf1 polyclonal antibody (Santa Cruz Biotechnology) at 4°C, and washed. After reaction with horseradish peroxidaseconjugated anti-goat IgG, immune complexes were visualized by using the ECL detection reagents (Amersham) following the manufacturer's suggested procedure. Simultaneously, normal goat IgG was used as a control. Proteasome assay The proteasome assays were performed after treatment of MKN-74 cells with troglitazone for 48 h. The medium was removed and the cells were washed several times before they were lysed. To measure the proteasome chymotrypsin peptidase activity, 10 µl of cellular extract (100 µg, prepared by brief sonication of cells and fractionation at 15 000g) was diluted in a cuvette containing 2 ml of 20 mM Hepes, 0.5 M EDTA, pH 8 and 0.035% SDS. The cell extracts contain 26S proteasome. The above mixture was incubated at 37°C before the addition of the fluorogenic substrate, 10 µM succinyl-Leu-LeuVal-Tyr-7-amido-4-methylcoumarin. Substrate hydrolysis was measured by continuous monitoring for fluorescence (emission at 460 nm, excitation at 380 nm) of the liberated 7-amido-4-methylcoumarin for 750 s as described.
22)
Statistical analysis The results are expressed as mean± SEM. Statistical analysis was performed by one-way analysis of variance followed by Fisher's LSD test. P<0.05 was considered statistically significant. MKN-28, MKN-45 or MKN-74 cells, the cell number at 48 h in the DMSO control groups was 4-fold higher than that at 0 h, indicating rapid cell growth, while in KATO-III, the cell number at 48 h in the DMSO control was not much higher than that at 0 h.
RESULTS
First
We next examined the cell cycle profiles in the four cell lines by flow cytometry. Fig. 3 illustrates the effects of troglitazone on the cell cycle profile in the four cell lines and the percentages of cells in G1, S and G2/M phase are shown in Table I . Flow cytometric analysis revealed that the population of G1-phase cells in all the cell lines 36 h after troglitazone at a dose of 100 µM was much larger than that of the DMSO control. It was also demonstrated that the population of S-phase cells in the four cell lines treated with troglitazone was much smaller than that of the DSMO control. These results suggest that troglitazone arrests cells at the G1 phase.
To evaluate the mechanism of the G1 arrest in gastric cancer cells by troglitazone, we examined the effects of troglitazone on the expression of CDKI, p21
Cip1/Waf1 and p27 Kip1 . Fig. 4 shows the time-course of expression of p21
Cip1/Waf1 and p27 Kip1 evaluated by western blotting in the four gastric cancer cell lines after troglitazone at a dose of 100 µM. Troglitazone increased the protein expression of p27
Kip1 in a time-dependent manner in all four cell lines, suggesting that p27
Kip1 may be involved in the G1 arrest by troglitazone in gastric cancer cells. p21
Cip1/Waf1 protein expression was also up-regulated by troglitazone in MKN-28, MKN-45 and MKN-74, but not in KATO-III.
Next, we tried to clarify the mechanism of the p27 Kip1 accumulation by troglitazone in gastric cancer cells. Because a recent report indicated that the ubiquitin-proteasome system plays a role in p27 Kip1 degradation, [23] [24] [25] we hypothesized that inhibition of proteasome is implicated in the p27
Kip1 accumulation by troglitazone in gastric cancer cells. Fig. 5 illustrates the effect of lactacystin, a selective proteasome inhibitor, on cell growth and p27
Kip1 protein levels in MKN-74. Lactacystin in a dose of 10 µM significantly inhibited the cell growth and increased the expression of p27 Kip1 , suggesting that inhibition of proteasome may induce growth arrest through an increase of p27 Kip1 , which is very similar to the cell behavior seen after troglitazone in gastric cancer cells. To test whether troglitazone inhibits proteasome activity, we examined the proteasome activity of MKN-74 cells treated with troglitazone. As can be seen in Fig. 6 , troglitazone dose-dependently inhibited the proteasome activity in MKN-74 cells.
DISCUSSION
We have demonstrated for the first time that human gastric cancer cells express PPARγ. 13) In that study, we showed that one cancer cell line, MKN-45, expresses PPARγ by RT-PCR, northern blot and western blot analy- 26) These results indicate that the expression of PPARγ in human gastric cancer cells is a common biological character.
With regard to the discrepancy between mRNA and protein data on PPARγ expression in two gastric cancer cell lines (MKN-28 and MKN-74) in Fig. 1 , we do not know the reason for the discrepancy. According to the paper by Sato et al., 26) they examined PPARγ expression in four different gastric cancer cell lines by northern and western blotting and obtained similar data to ours. The figure in the paper shows that MKN-28 cells express a little PPARγ mRNA and a large amount of PPARγ protein. This is similar to the results in our study. As to the discrepancy between PPARγ mRNA and protein levels, they did protein expression in each gastric cancer cell line by troglitazone. Western blot analyses were performed using anti-p21 polyclonal antibody. p21
Cip1/Waf1 protein expression was detected in gastric cancer cells at several time points after treatment with troglitazone at a dose of 100 µM. According to the information provided by Santa Cruz Biotechnology, the antibody used in this study reacts with PPARγ1 and PPARγ2 and, to a lesser extent, human PPARα and PPARβ in western blotting. Therefore, we cannot exclude the possibility that the antibody used might have cross-reacted with proteins other than PPARγ. One may speculate whether PPARγ is expressed in normal gastric epithelial cells or is specific to gastric cancer cells. With regard to this point, Braissant et al. 27) reported that rat normal gastric mucosa expressed PPARγ and Sato et al. have recently reported an immunohistochemical study of surgically resected gastric specimens showing that normal human gastric mucosa with intestinal metaplasia adjacent to cancer also expresses PPARγ. 26) These results suggest that not only gastric cancer cells, but also normal gastric epithelial cells express PPARγ.
In all the tested cell lines, troglitazone induced cell growth inhibition, suggesting that PPARγ activation by troglitazone caused the inhibition of cell growth. Flow cytometry revealed that troglitazone arrested gastric cancer cells at the G1 phase. It is therefore suggested that troglitazone-induced inhibition of cell growth depends upon the G1 arrest induced by troglitazone in gastric cancer cells. It has been shown that troglitazone evoked G1 arrest in human colon, pancreatic and breast cancer cells. 6, 14, 15) The G1 arrest observed after troglitazone treatment in gastric cancer cell lines further supports the idea that PPARγ activation arrests the cell cycle at G1 in a wide variety of cancer cells.
Little is known about the mechanism by which troglitazone induces G1 arrest. We have very recently demonstrated that troglitazone increased the protein level of p27 Kip1 , a cyclin-dependent kinase inhibitor, and antisense oligonucleotide against p27
Kip1 blocked the troglitazoneinduced cell growth arrest in human pancreatic cancer cells, strongly suggesting that p27
Kip1 is implicated in the cell growth arrest by troglitazone in pancreatic cancer cells. 14) These results suggested for the first time that p27
Kip1 mediates troglitazone-induced cell growth arrest. In the present study, we have examined whether p27 Kip1 Although we do not know in detail the mechanism of accumulation of p27
Kip1 by troglitazone, it has been reported that a ubiquitin-proteasome pathway is implicated in one of the posttranslational mechanisms of p27 Kip1 regulation. [23] [24] [25] Based upon this evidence, we hypothesized that troglitazone-mediated G1 arrest occurs through inhibition of the proteasome. To test this idea, we examined 1) if inhibition of the proteasome induces growth arrest, 2) if inhibition of the proteasome up-regulates p27 Kip1 and 3) if troglitazone inhibits proteasome activity. We found that lactacystin, a specific proteasome inhibitor, inhibited cell proliferation and up-regulated p27 Kip1 protein level in a breast cancer cell line, MDA-MB-157, 24) supporting the present finding that proteasome inhibition by lactacystin increased p27
Kip1 also in gastric cancer cells. The increase in p27
Kip1 protein may lead to the inhibition of cell growth in gastric cancer cells.
Next, we examined whether troglitazone inhibits proteasome activity and found that proteasome activity was significantly inhibited by troglitazone in a dose-dependent manner. The proteasome inhibition by troglitazone was observed at doses that caused cell growth inhibition and p27
Kip1 up-regulation in gastric cancer cells. These results suggest for the first time that troglitazone inhibits proteasome activity. We speculate that the inhibition of proteasome by troglitazone could lead to inhibition of the degradation process of p27 Kip1 , thereby resulting in the accumulation of p27
Kip1 protein. Thus, inhibition of proteasome may mediate troglitazone-induced growth arrest through p27
Kip1 accumulation.
